LHRH agonists in prostate cancer: frequency of treatment, serum testosterone measurement and castrate level: consensus opinion from a roundtable discussion
Authors:
- 11 April 2007
- journal article
- review article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 23 (5) , 1077-1080
Abstract
Background: Options for lowering testosterone in patients with prostate cancer include bilateral orchiectomy, oestrogens and luteinising hormone-releasing hormone (LHRH) agonists. LHRH agonists have become widely used in the treatment of prostate cancer.Roundtable assembly: In May 2006, a team of experts convened a roundtable assembly to discuss key issues associated with the use of LHRH agonists in the treatment of prostate cancer.Roundtable discussion: The discussion centred on the frequency of treatment with LHRH agonists, the role of serum testosterone (ST) measurement as part of routine follow-up, and the recommended castrate level of ST. Several formulations of LHRH agonists are available, including 3-month depots that coincide with visit frequency for prostate-specific antigen (PSA) testing. Appropriate monitoring of patients receiving LHRH agonists continues to be based on PSA levels. ST determination is not recommended as part of routine follow-up, and does not provide additional prognost...Keywords
This publication has 13 references indexed in Scilit:
- Hormone Therapy: Improving Therapy Decisions and MonitoringEuropean Urology Supplements, 2006
- EAU Guidelines on Prostate CancerEuropean Urology, 2005
- Endocrine treatment of prostate cancerThe Journal of Steroid Biochemistry and Molecular Biology, 2004
- Luteinizing hormone–releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implantUrology, 2003
- Reassessment of the definition of castrate levels of testosterone: implications for clinical decision makingUrology, 2000
- Single-Therapy Androgen Suppression in Men with Advanced Prostate CancerAnnals of Internal Medicine, 2000
- Effect of Orchidectomy on Serum Concentrations of Testosterone and Dihydrotestosterone in Patients with Prostatic CancerScandinavian Journal of Urology and Nephrology, 1992
- Comparison of LHRH Analogue (Zoladex) with Orchiectomy in Patients with Metastatic Prostatic CarcinomaBritish Journal of Urology, 1991
- Patients' choice of treatment in stage D prostate cancerUrology, 1989
- Phase III studies to compare goserelin (zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinomaUrology, 1989